Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 28, 2015 2:35 AM ET

Life Sciences Tools and Services

Company Overview of Gentris LLC

Company Overview

Gentris LLC provides pharmacogenomic (PGx) testing and biorepository services. Its PGx testing services include clinical genotyping assays, gene expression assays, next generation sequencing, tumor profiling, custom assay development and validation, clinical sample logistics, nucleic acid extraction from multiple tissue types, and biostorage and sample management services. The company’s services also include biomarker solutions, such as pharmacogenomics applying, genotyping, generation expression, next gen sequencing, bioinformatics, custom assay design, and consulting services; and integrated biorepository services, including biobanking, sample logistics, sample storage systems, and nucleic...

133 Southcenter Court

Suite 400

Morrisville, NC 27560

United States

Founded in 2001





Key Executives for Gentris LLC

Chief Executive Officer, President and Director
Founder and Director
Chief Operating Officer
Chief Scientific Officer and Vice President of Global Scientific Operations
Vice President of Diagnostics & Marketing
Compensation as of Fiscal Year 2015.

Gentris LLC Key Developments

Gentris Corporation Reports Unaudited Earnings Results for Second Quarter Ended June 30, 2014

Gentris Corporation reported unaudited earnings results for second quarter ended June 30, 2014. For the quarter, on non-GAAP basis, the company reported revenue was $1,719.1 million. Loss from operations was $1,324.9 million. Loss before income taxes was $509.6 million. Net loss was $509.6 million.

Gentris Corporation Announces Executive Appointments

Gentris Corporation announced the addition of Dr. Heath Knight as vice president, corporate development and Mr. Joseph Kessler, as chief operating officer. These two executives join the executive leadership team as the company anticipates its next phase of growth. Heath Knight, Ph.D., will lead business development, sales, and marketing. Her focus will be driving further expansion of the company's genomic testing and bio-repository services in domestic and international markets. A key focus will be in China where the company opened its first international facility in November, 2013. Dr. Knight was previously with Gentris as vice president of sales and marketing and left in 2008 to join Third Wave Technologies as executive director of genomic services and general manager of the newly formed pharmacogenomic Services business unit. She was recently strategic director of companion diagnostics for LabCorp's Clinical Trials. Over the past 15 years, Dr. Knight has held senior management positions in business development and sales as well laboratory operations in leading specialty genomic testing providers. She earned a Ph.D. degree in Human Genetics from the Medical College of Virginia and completed postdoctoral training at Baylor College of Medicine and the Mayo Clinic. Joseph Kessler, M.S., will head operations at Gentris' two laboratories, the company headquarters located in Research Triangle Park, NC and the newly opened testing and storage facility in Shanghai, China. Mr. Kessler has over 25 years leadership experience in clinical research and operations. Mr. Kessler joins Gentris from DaVita labs where he was senior director of laboratory operations and was responsible for oversight of their CAP/CLIA clinical testing laboratory and sample repository services.

Gentris Corporation Opens New Genomic Biomarker Laboratory in China

Gentris(R) Corporation announced that it has opened a new genomic biomarker testing and biorepository services laboratory in Shanghai, China. Gentris Shanghai will provide GCLP-compliant testing and biobanking services for global pharmaceutical clients under international standards. Gentris Shanghai will solve a critical need for pharmacogenomic (PGx) testing and clinical sample storage under international standards in China.

Similar Private Companies By Industry

Company Name Region
Covance Clinical Research Unit, Inc. United States
Open Biosystems, Inc. United States
ApoCell, Inc. United States
Pyxant Labs Inc. United States
California Healthcare Institute United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Gentris LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at